
[ASCO 2025] Daehwa’s Liporaxel gets green light for breast cancer indication expansion
CHICAGO, Ill. – By Kim Yun-mi, Korea Biomedical Review correspondent -- Expanded indications for oral paclitaxel (Liporaxel in trademark name) developed by Daehwa Pharmaceutical are on the horizon. At the American Society of Clinical Oncology 2025 Annual …